Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brazil Tightens Outsourcing Restrictions Just Months After Easing Them

Executive Summary

ANVISA's new resolution requires that companies importing finished drug products have their own quality control laboratory and warehouse.

You may also be interested in...



Latin America Regulatory Round-Up: A Red Tape Reduction In Brazil, Mexico

A recap of the latest Rx regulatory developments this summer (or winter) from Latin America regulators.

Brazil's Product Licensing Restrictions Eventually May Get Easier

Brazilian drug regulator Anvisa has made some changes over the years, but still restricts companies with approved Rx products from licensing them to another company.

Brazil, Mexico Taking Divergent Paths On Regulatory Reform

Anvisa is in the process of trying to reduce some of its red tape, but the excessive bureaucracy at COFEPRIS is likely to remain in place for the foreseeable future.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS124520

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel